Skip to Content
Biometric Research Program


Contact BRP
Show menu
Search this site
Last Updated:

Dr. Ana F. Best

Mathematical Statistician, Biostatistics Branch


Dr. Best has been a member of the Biometric Research Program since 2019. Prior to this, she completed a postodoctoral fellowship in the Biostatistics Branch of the NCI Division of Cancer Epidemiology and Genetics. She received her Ph.D. in Statistics from McGill University in 2015. Her current responsibilities in BRP include biomarker statistical review of clinical trial protocols and proposals for the use of biospecimens, membership on the iMATCH Diagnostic Selection Working Group and ComboMATCH Molecular Biomarkers and Specimen Management Committee, and participation in the NCI COVID-19 in Cancer Patients Study (NCCAPS) as a study statistician.

Research Interests:

Biomarkers and biomarker measurement error in clinical trial design and analysis, design and analysis for pooled specimen studies, survival analysis, risk prediction, cancer surveillance, cancer rate forecasting, cancer susceptibility syndromes.

CV (Updated Feb, 2022)

Selected Publications:

de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, Best AF, Savage SA. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic germline TP53 variants: an observational study, Lancet Oncology, 2021. 22(12): 1787-1789

Bhala S, Stewart DR, Kennerley V, Petkov VI, Rosenberg PS, Best AF. Incidence of benign meningiomas in the United States: current and future trends, JNCI Cancer Spectrum, 2021. 5(3): pkab035.

Oba L, Best AF, Mai PL, Achatz MI, Savage SA, Khincha PP. Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome, Familial Cancer, 2021. Online ahead of print.

Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021. 39(24): 2720-2731.

Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA. A pragmatic testing-eligibility framework for population mutation screening: The example of BRCA1/2. Cancer Epidemiology Biomarkers and Prevention. 2019. 28 (2): 293-302. PMID: 30692095

Best AF, Hilbert JE, Wood L, Martens WB, Nikolenko N, Marini-Bettolo C, Lochmuller H, Rosenberg PS, Moxley RT 3rd, Greene MH, Gadalla SM. Survival patterns and cancer determinants in families with myotonic dystrophy type 1. European Journal of Neurology. 2019. 26(1): 58-65. PMID: 30051542

Best AF, Haozous EA, Berrington de Gonzalez A, Chernyavskiy P, Freedman ND, Hartge P, Thomas D, Rosenberg PS, Shiels MS. Premature mortality projections in the USA through 2030: a modelling study. The Lancet Public Health. 2018. 3(8): e374-e385. PMID: 30037721

Best AF, Wolfson DB. Risk-set-sampling of left-truncated survival data. Canadian Journal of Statistics. 2017. 45(1): 4-28.

Alter BP, Best AF. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2020. 182:465-476. PMID: 32488392.

Stewart DR, Best AF, Williams GM, Harney LA, Carr AG, Harris AK, Kratz CP, Dehner LP, Messinger YH, Rosenberg PS, Hill DA, Schultz KAP. Neoplasm risk among individuals with a pathogenic germline variant in DICER1. Journal of Clnical Oncology. 2019. 37 (8): 668-676. PMID: 30714996

Tota J, Best AF, Zubsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi A. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. Journal of Clinical Oncology. 2019, 37(18): 1538-1546. PMID: 31026209

Khincha PP, Best AF, Fraumeni JF Jr, Loud JT, Savage SA, Achatz MI. Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome. European Journal of Cancer, 2019. 116: 199-206. PMID: 31212162

Wolfson DB, Best AF, Addona V, Wolfson J, Gadalla SM. Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy. Statistical Methods in Medical Research. 2019. 28(10-11): 3333-3345. PMID: 30293502

Ballinger ML, Best A, ..., Thomas DM, Savage SA. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: A meta-analysis. JAMA Oncology. 2017. 3(12): 1634-1639. PMID: 28772291

Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA. Risks of first and subsequent cancers among TP53 mutation carriersin the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016. 122(23): 3673-3681: PMID: 27496082

Dr. Ana Best

Office Address:
Room 5W114
9609 Medical Center Dr
Rockville, MD 20850

Contact Information:
Tel: (240) 276-7808
Fax: (240) 276-7888